RP-3 by Replimune for Lung Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Lung Cancer.

Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart activities – Biotech Investments

EQS-News: Affluent Medical SA / Key word(s): Study results Affluent Medical announces positive clinical results and further insights to enhance its strategy on Structural Heart

September 14, 2023

FTC doubles down in Welsh Carson anesthesia case to limit private equity’s physician buyouts

Lina Khan’s Federal Trade Commission is eager to make Big Physician a lot smaller. Last September, the FTC sued private equity firm Welsh, Carson, Anderson

February 12, 2024

Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness – Biotech Investments

Xlife Sciences AG / Key word(s): Market launch/Product Launch Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness 26.06.2024

June 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.